Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ETNB,190195000.0,20060300,10131000,,-14782000,,-14782000,4608000,0,-14739000,-14739000,,,,,,0,0,14739000,0,-43000,,-14782000,-14782000,328055000.0,8459000.0,190195000.0,500000.0,198654000.0,20000.0,25000.0,-137877000.0,-3000.0,557000.0,68007000.0,8459000.0,-3000.0,161000.0,197936000.0,121618000.0,4521000.0,-15406000.0,2450000.0,-15410000.0,216000.0,-4764000.0,216000.0,-30176000.0,-14982000.0,15000.0,2022000.0,-4000.0,,,189477000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1616616000,1616616000,1616616000,-72.334,-3.47,-3.7,-5.135135,-88.3,17.455555,1.544445,0.088478714,21.235544,-2.2355442,-0.105273694,381145696,-5.4755044,-0.21517552,15,America/New_York,EDT,-14400000,2,2.6472163,18.16 - 19.19,18.51,18.99,19.14,10,8,finmb_640272057,REGULAR,"89bio, Inc.",us_market,0,NGM,False,False,19.0,1630510451,0.48999977,18.75,19.19,18.16,118709,NasdaqGM,"89bio, Inc.",USD,101085,69666,4.3,0.29251704,14.7 - 42.36,-23.36,-0.55146366,14.7,42.36,,,,42.36,14.7,17.46,21.24,101.08k,69.67k,20.06M,,8.42M,1.20%,100.94%,1.42M,12.09,14.70%,7.10%,1.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-23.31%,-39.79%,,,,,-53.33M,-53.74M,-72.33,,189.62M,9.45,,,23.40,-88.30,-53.47M,-33.72M,Value,94104,Healthcare,26,9,9,"89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.",San Francisco,415 500 4614,CA,8,1609372800,1622505600,6,United States,http://www.89bio.com,86400,8,142 Sansome Street,Biotechnology,2nd Floor
t-1,ETNB,202961000.0,20060300,8770000,,-12663000,,-12581000,3777000,0,-12547000,-12547000,,,,,,-82000,0,12547000,0,-116000,,-12581000,-12581000,326046000.0,8113000.0,202961000.0,600000.0,211074000.0,20000.0,25000.0,-123095000.0,-10000.0,706000.0,98183000.0,8113000.0,-10000.0,166000.0,210202000.0,106446000.0,2065000.0,-29026000.0,-1673000.0,-29028000.0,-312000.0,-1227000.0,216000.0,-43368000.0,-14028000.0,13000.0,1364000.0,-2000.0,-312000.0,,202089000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1616616000,1616616000,1616616000,-72.334,-3.47,-3.7,-5.135135,-88.3,17.455555,1.544445,0.088478714,21.235544,-2.2355442,-0.105273694,381145696,-5.4755044,-0.21517552,15,America/New_York,EDT,-14400000,2,2.6472163,18.16 - 19.19,18.51,18.99,19.14,10,8,finmb_640272057,REGULAR,"89bio, Inc.",us_market,0,NGM,False,False,19.0,1630510451,0.48999977,18.75,19.19,18.16,118709,NasdaqGM,"89bio, Inc.",USD,101085,69666,4.3,0.29251704,14.7 - 42.36,-23.36,-0.55146366,14.7,42.36,,,,42.36,14.7,17.46,21.24,101.08k,69.67k,20.06M,,8.42M,1.20%,100.94%,1.42M,12.09,14.70%,7.10%,1.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-23.31%,-39.79%,,,,,-53.33M,-53.74M,-72.33,,189.62M,9.45,,,23.40,-88.30,-53.47M,-33.72M,Value,94104,Healthcare,26,9,9,"89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.",San Francisco,415 500 4614,CA,8,1609372800,1622505600,6,United States,http://www.89bio.com,86400,8,142 Sansome Street,Biotechnology,2nd Floor
t-2,ETNB,214004000.0,20060300,11208000,,-14579000,,-14603000,3225000,0,-14433000,-14433000,,,,,,24000,0,14433000,0,-146000,,-14603000,-14603000,324501000.0,9424000.0,214004000.0,600000.0,223428000.0,20000.0,25000.0,-110514000.0,-3000.0,713000.0,141551000.0,9424000.0,-3000.0,177000.0,222538000.0,77602000.0,4086000.0,-71982000.0,681000.0,-71999000.0,158292000.0,-351000.0,158292000.0,73353000.0,-12940000.0,18000.0,1238000.0,-17000.0,-312000.0,,213114000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1616616000,1616616000,1616616000,-72.334,-3.47,-3.7,-5.135135,-88.3,17.455555,1.544445,0.088478714,21.235544,-2.2355442,-0.105273694,381145696,-5.4755044,-0.21517552,15,America/New_York,EDT,-14400000,2,2.6472163,18.16 - 19.19,18.51,18.99,19.14,10,8,finmb_640272057,REGULAR,"89bio, Inc.",us_market,0,NGM,False,False,19.0,1630510451,0.48999977,18.75,19.19,18.16,118709,NasdaqGM,"89bio, Inc.",USD,101085,69666,4.3,0.29251704,14.7 - 42.36,-23.36,-0.55146366,14.7,42.36,,,,42.36,14.7,17.46,21.24,101.08k,69.67k,20.06M,,8.42M,1.20%,100.94%,1.42M,12.09,14.70%,7.10%,1.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-23.31%,-39.79%,,,,,-53.33M,-53.74M,-72.33,,189.62M,9.45,,,23.40,-88.30,-53.47M,-33.72M,Value,94104,Healthcare,26,9,9,"89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.",San Francisco,415 500 4614,CA,8,1609372800,1622505600,6,United States,http://www.89bio.com,86400,8,142 Sansome Street,Biotechnology,2nd Floor
t-3,ETNB,69771000.0,20060300,8443000,,-11771000,,-11771000,3230000,0,-11673000,-11673000,,,,,,0,0,11673000,0,-98000,,-11771000,-11771000,165668000.0,6791000.0,69771000.0,700000.0,76562000.0,14000.0,24000.0,-95911000.0,,1080000.0,68199000.0,6791000.0,,191000.0,75291000.0,5697000.0,3070000.0,-5698000.0,-943000.0,-5744000.0,-65000.0,185000.0,96000.0,-17333000.0,-11524000.0,17000.0,911000.0,-46000.0,-312000.0,-161000.0,68500000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1616616000,1616616000,1616616000,-72.334,-3.47,-3.7,-5.135135,-88.3,17.455555,1.544445,0.088478714,21.235544,-2.2355442,-0.105273694,381145696,-5.4755044,-0.21517552,15,America/New_York,EDT,-14400000,2,2.6472163,18.16 - 19.19,18.51,18.99,19.14,10,8,finmb_640272057,REGULAR,"89bio, Inc.",us_market,0,NGM,False,False,19.0,1630510451,0.48999977,18.75,19.19,18.16,118709,NasdaqGM,"89bio, Inc.",USD,101085,69666,4.3,0.29251704,14.7 - 42.36,-23.36,-0.55146366,14.7,42.36,,,,42.36,14.7,17.46,21.24,101.08k,69.67k,20.06M,,8.42M,1.20%,100.94%,1.42M,12.09,14.70%,7.10%,1.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-23.31%,-39.79%,,,,,-53.33M,-53.74M,-72.33,,189.62M,9.45,,,23.40,-88.30,-53.47M,-33.72M,Value,94104,Healthcare,26,9,9,"89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.",San Francisco,415 500 4614,CA,8,1609372800,1622505600,6,United States,http://www.89bio.com,86400,8,142 Sansome Street,Biotechnology,2nd Floor
